[HTML][HTML] Evidence of tenofovir resistance in chronic hepatitis B virus (HBV) infection: An observational case series of South African adults
…, M de Cesare, M Andersson, S Gabriel… - Journal of Clinical …, 2020 - Elsevier
Introduction Tenofovir disoproxil fumarate (TDF) is widely recommended for treatment of
chronic hepatitis B virus (HBV) infection because it is safe, affordable and has a high genetic …
chronic hepatitis B virus (HBV) infection because it is safe, affordable and has a high genetic …
[HTML][HTML] Treatment advantage in HBV/HIV coinfection compared to HBV monoinfection in a South African cohort
Objectives Prompted by international targets for elimination of hepatitis B virus (HBV), we
set out to characterise individuals with HBV monoinfection vs. those coinfected with HBV/HIV, …
set out to characterise individuals with HBV monoinfection vs. those coinfected with HBV/HIV, …
Use of second Anti-Tumour Necrosis Factor Agent in Inflammatory Bowel Disease When First Agent Failed: A South African Retrospective Study
…, A Titis, S Fortuin, S Gabriel… - Archives of …, 2022 - scientificarchives.com
Background: Inflammatory bowel disease is a chronic relapsing and remitting inflammation
of the bowel. Tumour necrosis factor α-antagonists are safe and effective in the treatment of …
of the bowel. Tumour necrosis factor α-antagonists are safe and effective in the treatment of …
Use of second anti-TNF agent in inflammatory bowel disease when first agent failed: A South African retrospective study
E Fredericks, A Titus, S Fortuin, S Gabriel, M Setshedi - 2022 - researchsquare.com
Background: Inflammatory bowel disease is a chronic relapsing and remitting inflammation
of the bowel. Tumour necrosis factor α-antagonists are safe and effective in the treatment of …
of the bowel. Tumour necrosis factor α-antagonists are safe and effective in the treatment of …
[PDF][PDF] Tandem use of Anti-TNF Agents in Patients with IBD who Fail First Line Anti-TNF Therapy: Real Life Lessons from a National Database.
E Fredericks, A Titus, S Gabriel, W De Villiers - 2021 - scholar.archive.org
Background: In ammatory bowel disease (IBD) is a chronic relapsing and remitting in ammation
of the bowel. Biologic therapy is safe and effective in IBD. Anti-TNF agents were the rst …
of the bowel. Biologic therapy is safe and effective in IBD. Anti-TNF agents were the rst …
[HTML][HTML] IAP ASSA SAGES Congress 2019
…, K Coovadia, C van Rensburg, S Gabriel - S Afr Med J, 2019 - scielo.org.za
Background. The burden of gastroenterological disease in South Africa is increasing. With
this increased burden come increased challenges in service delivery and patient care. In …
this increased burden come increased challenges in service delivery and patient care. In …
[PDF][PDF] IAP ASSA SAGES Congress 2019: 16-20 August, Cape Town International Convention Centre
L Fyffe - South African Medical Journal, 2019 - samj.org.za
Background. The burden of gastroenterological disease in South Africa is increasing. With
this increased burden come increased challenges in service delivery and patient care. In …
this increased burden come increased challenges in service delivery and patient care. In …
[PDF][PDF] SAGES Congress 2018, 8-11 August, The Campus, The Forum, Bryanston, Johannesburg
L Fyffe - South African Medical Journal, 2018 - samj.org.za
Background. Azathioprine is an immunosuppressant used in the treatment of inflammatory
bowel disease (IBD). However, its sideeffects have raised concern, as> 20% of treated …
bowel disease (IBD). However, its sideeffects have raised concern, as> 20% of treated …
IBD Interest Group Meeting
T Kahn - South African Gastroenterology Review, 2019 - journals.co.za
The IBD Interest Group Meeting was held at the Vineyard Hotel in Cape Town, on a sunny
winter’s Saturday in June. This was the 13th Inflammatory Bowel Disease (IBD) interest group …
winter’s Saturday in June. This was the 13th Inflammatory Bowel Disease (IBD) interest group …